Conclusion: Findings suggest smaller decreases in ASD diagnoses compared to earlier reviews. Future research is needed as concerns remain for impaired individuals without a diagnosis.
PubMed 30852784 ↗S-23
The short answer. People are split on S-23 — 54% of 34 say it helped. It is most often used for performance: 93% of 29 reports say that improved. It is well studied — 6 meta-analyses on PubMed. The most common complaint is suppression. It is not an approved supplement and carries real risks.
From 83 mentions in total — the rest didn't say how it went and aren't counted.
What S-23 does, according to users
Of the people who reported each effect, the share who said it got better.
7 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 6 meta-analyses on PubMed ↗ · 26 randomized trials ↗
Conclusion: According to the data retrieved from patients who underwent MBS compared to nonoperated patients suffering from obesity, the overall risk for malignancy was lower in the MBS group. Additional information collected in this study revealed the behavior of specific types of cancer in response to induced weight loss by operative means. The benefit of surgery in patients suffering from obesity is not restricted to the improvement of obesity morbidity alone.
PubMed 39581814 ↗Conclusion: Regarding unipolar affective disorder this study confirms what we have shown for bipolar disorders in earlier studies: schizoaffective disorder falls between schizophrenia and affective disorders, and there are relevant quantitative differences in key illness characteristics, which supports the validity of the schizoaffective disorder concept. Contrary to our expectations heterogeneity is not larger in SAD than in UD and not substantially higher than in S. Lower reliability of the diagnosis of SAD therefore cannot be ascribed to higher variability of illness characteristics in SAD.
PubMed 26599364 ↗Conclusion: Trimetazidine efficacy was comparable to that of other non-heart-rate-lowering antianginal treatments in patients with stable angina pectoris.
PubMed 22122948 ↗4 human trials on ClinicalTrials.gov test S-23, 2 recruiting now. See all on ClinicalTrials.gov ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“It personally was my favorite cycle. The strength and size gains were better than RAD.”
“S-23 is very strong but the side effects suck ass for a ton of people, some can use it fine but for others (like me) it has like tren level sides and simply isn't worth it.”
“Really strong, be sure to have test base. Really acnee prone sarm. It felt like tren for me.”
“I get amazing results from rad140 and almost none from s23 which is supposed to be one of the strongest.”
Top discussions (5)
- Any experience stacking S-23 and LGD? ↗
- Reconstituting SARMs ↗
- Stacking up on Yk-11, MK-677, Rad-140, and S-23. Any thoughts or concerns I should be worried about? Including TRT, and Microdosing IGF 100mcmg’s a day. ↗
- what are some peptides that show physical changes to the body? ↗
- List of SARMs (known) half life and how much you will have in your body ↗
Other options for performance
Sources
- User reports: 83 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate